Here are relevant reports on : herbal-medicine-market
-
Asia-Pacific Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) – Forecast to 2017
The market is broadly classified into two segments, namely, diagnostic and therapeutic; the former dominated with about 80.7% share in 2012. Radioisotopes in the diagnostic market are categorized as SPECT and PET. Technetium 99m (Tc-99m) dominated the SPECT radioisotope market in 2012, followed by thallium–201(Tl-201), gallium–67 (Ga-67), and iodine-123 (I-123). SPECT is majorly used in cardiology-related diagnosis; it is poised to grow at a CAGR of 10.2% from 2012 to 2017. The radiopharmaceuticals market in the Asia-Pacific region was valued at $500.8 million in 2012; it is poised to reach $824.9million in 2017 at a CAGR of 10.5%.
- Published: May 2013
- Price: $ 4950
- TOC Available:
-
Mice Model Market by Model Type (Inbred, Outbred, Hybrid), Service (Breeding, Rederivation), Application (Personalized Medicine), Technology (Microinjection, CRISPR/Cas9), Therapeutic Area (Oncology, Neurology), End User (CROs) - Global Forecast to 2030
The global mice model market, valued at US$1.53 billion in 2024, stood at US$1.70 billion in 2025 and is projected to advance at a resilient CAGR of 10.0% from 2025 to 2030, culminating in a forecasted valuation of US$2.74 billion by the end of the period. The growth of this market is driven by several factors, such as rising adoption of mice models in preclinical studies due to genetic & physiological versatility; the increasing demand for mouse clinical trials; the rising demand for personalized medicine in oncology; and advancements in genetic engineering.
- Published: July 2025
- Price: $ 4950
- TOC Available:
-
Latin American Bioinformatics Market by Sector (Agriculture, Molecular Medicine, Research & Animal), Segment (Sequencing Platforms, Knowledge Management Tools & Data Analysis Services) & Application (Genomics, Proteomics & Drug Design) - Forecasts to 2017
The Latin American bioinformatics market was valued at $242 million in 2012 and is poised to reach $627 million by 2017, at a CAGR of 22%. The Latin American bioinformatics market displays lucrative growth potential. It is propelled by the rising number of training and development programs on usage of bioinformatics tools, which leads to an increase in the use of bioinformatics tools by industrial and academic bioinformaticians in life sciences research. In addition, the market is further driven by the high concentration of bioinformatics research institutes in Latin America that aim to facilitate the use of bioinformatics in life sciences research. However, the dearth of skilled personnel and facilities to ensure the proper use of bioinformatics products and services and the dearth of advanced and innovative bioinformatics tools and algorithms are limiting the growth of the bioinformatics market in Latin America.
- Published: March 2014
- Price: $ 4950
- TOC Available:
-
Advanced Visualization Market by Type (Enterprise, Standalone), Modality (MRI, CT, PET, Ultrasound, Radiotherapy, Nuclear Medicine), Application (Radiology, Oncology, Neuro), End User (Hospital, ASC, Diagnostic Center) & Region - Global Forecast to 2029
The global advanced visualization market, valued at US$3.36 billion in 2023, stood at US$3.78 billion in 2024 and is projected to advance at a resilient CAGR of 11.7% from 2024 to 2029, culminating in a forecasted valuation of US$6.55 billion by the end of the period. Technological advancements in advanced visualization tools, the rising need for early detection of diseases, and the growing support from government & private organizations are key factors driving the market growth.
- Published: January 2025
- Price: $ 4950
- TOC Available:
-
Europe Artificial Intelligence (AI) in Healthcare Market by Offering (Integrated), Function (Diagnosis, Genomic, Precision Medicine, Radiation, Telehealth, RPM, Immunotherapy, Supply Chain), Application (Clinical), End User (Hospitals) - Forecast to 2030
The Europe Artificial Intelligence (AI) in Healthcare Market, valued at USD 4.20 billion in 2024, stood at USD 6.12 billion in 2025 and is projected to advance at a resilient CAGR of 39.0% from 2025 to 2030, culminating in a forecasted valuation of USD 31.72 billion by the end of the period. This growth is driven by strong regulatory support for digital transformation and the rising adoption of AI-enabled clinical workflows across European health systems.
- Published: November 2026
- Price: $ 4950
- TOC Available:
-
Precision Medicine Software Market by Delivery Mode (On-Premise & Cloud-Based), End User (Healthcare Providers, Research Centers & Government Institutes, Pharmaceutical & Biotechnology Companies), Application, and Region - Global Forecast to 2024
The precision medicine software market is projected to reach USD 2.0 billion by 2024, at a CAGR of 11.5%. Factors such as the rising government funding in precision medicine initiatives, partnerships among pharmaceutical and software companies, the entry of new players & VC funding, and growth in the number of cancer patients are driving the growth of the precision medicine software market. However, the high cost of deployment, issues related to the secure storage of large volumes of sequenced data, lack of reimbursement for precision medicine-based treatments, and the dearth of skilled IT professionals in healthcare are expected to restrain market growth to a certain extent in the coming years. Syapse, Inc. (US), 2bPrecise LLC (Israel), Foundation Medicine, Inc. (US), Fabric Genomics (US), SOPHiA GENETICS SA (Switzerland), PierianDx, Inc. (US), N-of-One, Inc. (US), Human Longevity, Inc. (US), Translational Software, Inc. (US), Sunquest Information Systems Inc. (US), Gene42, Inc. (Canada), LifeOmic Health, LLC (US), NantHealth, Inc. (US), Tempus Labs, Inc. (US), Flatiron Health, Inc. (US), IBM Watson Group (US), and Koninklijke Philips N.V. (Netherlands)
- Published: March 2019
- Price: $ 4950
- TOC Available:
-
US Artificial Intelligence (AI) in Healthcare Market by Offering (Integrated), Function (Diagnosis, Genomic, Precision Medicine, Radiation, Telehealth, Immunotherapy, Pharmacy, Supply Chain), Application (Clinical), End User (Hospitals) - Forecast to 2030
The US artificial intelligence (AI) in healthcare market, valued at US$5.98 billion in 2024, stood at US$8.65 billion in 2025 and is projected to advance at a resilient CAGR of 38.0% from 2025 to 2030, culminating in a forecasted valuation of US$43.30 billion by the end of the period. Market growth is driven by rising demand from providers for automation, nationwide labor shortages, increasing clinical complexity, and strong investment in predictive analytics, imaging AI, and GenAI.
- Published: November 2026
- Price: $ 4950
- TOC Available:
-
Electroceuticals Market / Bioelectric Medicine Market by Product (Cardiac Pacemakers, ICD, Cochlear Implant, Neuromodulation (Deep Brain Stimulation)), Type (Implantable, Non-Invasive), Application (Arrhythmia, Heart Failure, Epilepsy) & Region - Global Forecast to 2029
The global electroceuticals market, valued at US$21.9 billion in 2023, stood at US$23.9 billion in 2024 and is projected to advance at a resilient CAGR of 7.0% from 2024 to 2029, culminating in a forecasted valuation of US$33.6 billion by the end of the period. Growth of the overall market is largely driven by the increasing incidence of cardiovascular, hearing loss and neurological disorders, increasing research in these field of disorders, and rising awareness regarding electroceuticals devices.
- Published: March 2024
- Price: $ 4950
- TOC Available:
-
Precision Diagnostics & Medicine Market by Diagnostic Testing (Genetic, DTC), Diagnostics Indication (Oncology, Neurology, Immunology), Therapeutic Products (Inhibitors, mAbs, CGT), Indication (Oncology, Rare Disease, Infectious) - Global Forecast to 2029
The global precision diagnostics and medicine market, valued at US$132.46 billion in 2023, stood at US$145.53 billion in 2024 and is projected to advance at a resilient CAGR of 11.1% from 2024 to 2029, culminating in a forecasted valuation of US$246.66 billion by the end of the period. Factors such as the growing integration of AI and ML to enhance precision diagnostics and medicine development supported by rising collaborations between pharmaceutical and diagnostics companies to improve precision healthcare and the rise in direct-to-consumer testing are driving the growth in the market.
- Published: January 2025
- Price: $ 4950
- TOC Available:
-
Cell Line Development Market by Product (Equipment, Media and Reagents), Source, type & by Application ( Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, Research, Drug Discovery) - Analysis & Global Forecast to 2019
The global cell line development market is expected to reach 3.96 billion by 2019 from $2.2 billion in 2014, and is expected to grow at a CAGR of 12.5% from 2014 to 2019. The market is dominated by North America, followed by Europe, Asia, and Rest of the World (RoW). North America is expected to maintain its leadership position in the market in the coming years.
- Published: September 2014
- Price: $ 4950
- TOC Available:
Records 21 to 30 of 50